IRCT20201107049296N2 IRCT 2023-08-19 Iran University of Medical Sciences Evaluation of the effect of oral L-Carnitine on liver enzymes in children diagnosed with ALL Evaluation of the effect of oral L-Carnitine on liver enzymes in children diagnosed with ALL in the maintenance phase of therapy: A randomized clinical trial 2023-09-06 anticipated 98 Complete https://irct.ir/trial/72097 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, the stratified block randomization method will be used using blocks with a size of 4 and stratified according to age. We will use the site https://www.sealedenvelope.com to provide random sequences. For the sequence concealment, it will be given to an independent individual and will be revealed case by case to the project researcher in coded form with A and B labels, Blinding description: Blinding will be done using a placebo syrup identical in form to the original drug. Allocation between the groups is done based on the coded labels A and B on the glass of syrups, and only the independent person responsible for coding is aware of the type of labels. 2-3 Acute lymphoblastic leukaemia. Intervention 1: Intervention group: L-carnitine syrup (َAlborz pharmaceutical company, Iran) with a dose of 50 mg/Kg will be given in three times a day every 8 hours for a period of two months. The chemotherapy protocol will be weekly methotrexate at a dose of 20 mg/m2 (body surface) and 6 mercaptopurine daily at a dose of mg/m2 (body surface). Intervention 2: Control group: A placebo of the same shape and color in the same package as the intervention drugs (َAlborz pharmaceutical company, Iran) will be used in three divided doses every 8 hours for a period of two months. The chemotherapy protocol will be weekly methotrexate at a dose of 20 mg/m2 (body surface) and 6 mercaptopurine daily at a dose of mg/m2 (body surface). No - There is not a plan to make this available Justification or reason for not sharing IPD is Ownership of the data rests with the study sponsor.